UBS O'Connor’s Sage Therapeutics SAGE Stock Holding History

UBS O'Connor’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-20,000	Closed	-$603K	–	480
2016 Q2	$603K	Sell	20,000 -19,280	-49%	-$643K	0.01%	334
2016 Q1	$1.26M	Buy	+39,280	New	+$1.38M	0.01%	349

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS O'Connor's SAGE Position: Q3 2016 in Review

UBS O'Connor sold out of Sage Therapeutics (SAGE) in Q3 2016, closing a stake of 20,000 shares — an estimated $603K sold.

UBS O'Connor first reported a position in SAGE in Q1 2016 and held it in 2 quarters. The position peaked at $1.26M in Q1 2016. 154 funds tracked by Wall St. Rank hold SAGE as of Q3 2016.

UBS O'Connor reported no remaining Sage Therapeutics position as of Q3 2016 after selling out during the quarter.
UBS O'Connor sold 20,000 Sage Therapeutics shares in Q3 2016, an estimated $603K.
UBS O'Connor first reported a position in Sage Therapeutics in Q1 2016 and held it in 2 quarters.
UBS O'Connor's Sage Therapeutics position peaked at $1.26M in Q1 2016.
154 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.